RB Capital Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $243K | Buy |
10,083
+21
| +0.2% | +$549 | 0.05% | 180 |
|
|
2026
Q1 | $283K | Buy |
10,062
+256
| +3% | +$6.82K | 0.06% | 158 |
|
|
2025
Q4 | $244K | Buy |
9,806
+234
| +2% | +$5.9K | 0.05% | 172 |
|
|
2025
Q3 | $244K | Sell |
9,572
-567
| -6% | -$14K | 0.05% | 167 |
|
|
2025
Q2 | $246K | Sell |
10,139
-1,683
| -14% | -$39.2K | 0.06% | 164 |
|
|
2025
Q1 | $300K | Sell |
11,822
-709
| -6% | -$18.6K | 0.07% | 149 |
|
|
2024
Q4 | $332K | Sell |
12,531
-339
| -3% | -$9.2K | 0.08% | 140 |
|
|
2024
Q3 | $372K | Sell |
12,870
-314
| -2% | -$9.16K | 0.09% | 134 |
|
|
2024
Q2 | $369K | Sell |
13,184
-92
| -0.7% | -$2.53K | 0.09% | 131 |
|
|
2024
Q1 | $368K | Buy |
13,276
+4,754
| +56% | +$132K | 0.1% | 137 |
|
|
2023
Q4 | $245K | Sell |
8,522
-2,823
| -25% | -$85.3K | 0.07% | 155 |
|
|
2023
Q3 | $376K | Buy |
11,345
+144
| +1% | +$5.09K | 0.12% | 123 |
|
|
2023
Q2 | $411K | Buy |
11,201
+2,145
| +24% | +$83.5K | 0.12% | 117 |
|
|
2023
Q1 | $370K | Buy |
9,056
+650
| +8% | +$28.1K | 0.12% | 130 |
|
|
2022
Q4 | $431K | Buy |
8,406
+166
| +2% | +$7.96K | 0.15% | 111 |
|
|
2022
Q3 | $361K | Buy |
8,240
+1,849
| +29% | +$89.8K | 0.14% | 119 |
|
|
2022
Q2 | $335K | Buy |
6,391
+945
| +17% | +$48.2K | 0.12% | 129 |
|
|
2022
Q1 | $282K | Buy |
5,446
+341
| +7% | +$17.7K | 0.09% | 140 |
|
|
2021
Q4 | $301K | Sell |
5,105
-256
| -5% | -$12.7K | 0.09% | 138 |
|
|
2021
Q3 | $231K | Sell |
5,361
-919
| -15% | -$40.7K | 0.09% | 152 |
|
|
2021
Q2 | $246K | Sell |
6,280
-20
| -0.3% | -$778 | 0.09% | 145 |
|
|
2021
Q1 | $228K | Sell |
6,300
-395
| -6% | -$14K | 0.1% | 135 |
|
|
2020
Q4 | $246K | Sell |
6,695
-122
| -2% | -$4.47K | 0.11% | 124 |
|
|
2020
Q3 | $238K | Buy |
+6,817
| New | +$239K | 0.11% | 127 |
|
|
2020
Q2 | – | Sell |
-7,875
| Closed | -$246K | – | 149 |
|
|
2020
Q1 | $246K | Buy |
+7,875
| New | +$268K | 0.16% | 110 |
|
|
2019
Q3 | – | Sell |
-4,935
| Closed | -$203K | – | 143 |
|
|
2019
Q2 | $203K | Buy |
+4,935
| New | +$196K | 0.15% | 116 |
|
|
2018
Q3 | – | Sell |
-5,956
| Closed | -$205K | – | 134 |
|
|
2018
Q2 | $205K | Sell |
5,956
-587
| -9% | -$20.1K | 0.15% | 128 |
|
|
2018
Q1 | $220K | Sell |
6,543
-519
| -7% | -$17.8K | 0.17% | 118 |
|
|
2017
Q4 | $243K | Sell |
7,062
-16
| -0.2% | -$546 | 0.17% | 108 |
|
|
2017
Q3 | $240K | Sell |
7,078
-2,913
| -29% | -$93.6K | 0.19% | 103 |
|
|
2017
Q2 | $318K | Sell |
9,991
-82
| -0.8% | -$2.59K | 0.27% | 85 |
|
|
2017
Q1 | $327K | Sell |
10,073
-329
| -3% | -$10.4K | 0.31% | 80 |
|
|
2016
Q4 | $321K | Buy |
+10,402
| New | +$318K | 0.32% | 80 |
|
Other funds holding PFE
RB Capital Management's PFE Position: Q2 2026 in Review
RB Capital Management increased its Pfizer (PFE) stake by 0.21% in Q2 2026, buying an estimated $549 and bringing the position to 10,083 shares worth $243K. The position accounts for 0.05% of the portfolio, ranked #180.
RB Capital Management first reported a position in PFE in Q4 2016 and has held it in 33 quarters since. The position peaked at $431K in Q4 2022. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- RB Capital Management held 10,083 shares of Pfizer worth $243K as of Q2 2026.
- RB Capital Management bought 21 Pfizer shares in Q2 2026, an estimated $549.
- Pfizer made up 0.05% of RB Capital Management's portfolio in Q2 2026, its #180 holding.
- RB Capital Management first reported a position in Pfizer in Q4 2016 and has held it in 33 quarters since.
- RB Capital Management's Pfizer position peaked at $431K in Q4 2022.
- 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on RB Capital Management's 13F filing for Q2 2026, filed 18 Aug 2026.